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a double balloon system introduced to optimize dose 
distribution. 
Toxicity and long-term oncological results: In the neo-
adjuvant setting, grade 3 radiation proctitis is observed in 
less than 0.5% of treated cases 7-10 days after treatment 
completion. In the boost setting, proctitis is observed 3-4 
weeks after the HDREBT treatment and included rectal 
bleeding in 25% of the patients, out of which 10% with 
anticoagulation required transfusion and plasma-argon 
therapy. In 3 patients with circumferential tumors, rectal 
stenosis was documented. Rectal ulcerations can be observed 
5-9 months after treatment but do improve over time. 
Overall for low T2 and T3 tumors, HDREBT resulted with a 
pCR rate of 27%, with the local recurrence of 4.8 % at 5 years 
with a median follow up time of 62 months. For the medically 
unfitted patients, with HDREBT used as a boost, the local 
control is 65% at a median 28 months follow up time. 
Conclusion: In the present era of rectal preservation, the 
HDEBT represents a highly targeted radiation modality that is 
effective as neo-adjuvant and boost treatment modalities for 
patients with rectal cancer. 
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Surgery main Treatment of rectal cancer often combined 
with neoadjuvant (chemo) radiotherapy (CRT).  
Despite improvement in local control for T2-3(4) tumors, CRT 
failed to improve conservative treatment in rectal cancer. 
Anterior resection is often associated with suboptimal bowel 
function. Organ preservation (whole rectum + anus) is gaining 
interest mainly for early (T1) T2 T3 tumors. 
CXB: a unique technique of trans-rectal endoscopic 
Brachytherapy Evidence Based.  
Mainly pioneered by Papillon in the 1970s the technique is 
presenting a renaissance since 2009 (1) with the manufacture 
of a new machine delivering high dose rate of 50 Kvp X-rays( 
Papillon 50TM). Under direct endoscopic vision control it is 
possible to deliver 30 Gy in 2 minutes in a well-targeted small 
volume (5 cm3). It is a fully ambulatory treatment feasible at 
any age with very low toxicity. The dose distribution is better 
than with Iridium endoluminal HDR brachytherapy and 
radioprotection is easier. The Lyon R 96-02 randomized trial 
(2-3) has demonstrated with a 10 year follow-up that CXB 
boost combined with External beam RT in T2 -3 low rectum 
was able to increase by 30% the rate of clinical complete 
response, of sphincter saving surgery and of organ 
preservation in case of cCR. The rate of perirectal nodal 
relapse is below 5%. 
Present results in France and UK show good results for 
organ preservation in selected T1 T2 and early T3  
In T1 N0 (or malignant polyps) treated with local Excision 
first (63 pts between 1986-2012 in Lyon and Nice), adjuvant 
CXB (50 Gy/ 3 fr/ 3w) achieved local control in 95% of cases 
with good bowel function. In T2 T3 less than ½ circumference 
and < 5cm diameter a combination of CXB and EBRT (or CRT), 
mainly in elderly frail patients, achieved cCR in close to 90% 
of cases (Lyon-Nice: 120 pts) with less than 20% local relapse 
very exceptional in perirectal lymph nodes (4-5). In 
Clatterbridge-Liverppool same results were achieved in the 
recent past years in more than 150 pts. Such combined CXB+ 
CRT appears as a very good option for frail patients or for 
younger patients adamantly refusing an invasive surgery.  
Many challenges remain open 
In operable patients the upcoming OPERA randomized trial 
will like the Lyon R96-02 try to show that CXB in addition to 
CRT (CAP 45) may achieve in T2 T3a-b at least 40% of organ 
preservation with good bowel function. The new machine 
Papillon+TM will bring some technical improvements. But the 
most important issue is that radiation oncologists willing to 
use CXB must get a good clinical practice of rigid rectoscopy 
on an ambulatory basis. 
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In the treatment of rectal cancer, total mesorectal excision 
surgery is now the standard of care. In most patients, surgery 
will be preceded by external beam radiotherapy (EBRT), 
either in a short course (25 Gy/5 fractions) or in a 
conventional schedule (45-50 Gy/25 fractions) with 
chemotherapy. Brachytherapy (BT) is an appealing 
alternative to EBRT.  In comparison to the EBRT, it offers the 
advantage of delivering a high dose of radiation with a rapid 
dose fall-off around the site of interest (tumor target). This 
results in the sparing of normal tissues such as small bowel 
but also the bladder, the prostate, anal sphincter and skin.  
In order to understand why brachytherapy may work as 
replacement for external beam radiotherapy, an exact target 
volume definition for rectal cancer is required, based on 
precise data on the local recurrence patterns. The decision 
which nodal regions should be included in the clinical target 
volume is often topic of discussion. In general, it can be 
stated that the highest risk of lymph node involvement is in 
the mesorectal fat. In addition, the presacral space and the 
internal iliac region are at risk. Depending on the exact 
localization and tumor stage, the obturator nodes, the 
external iliac nodes and the inguinal nodes may sometimes be 
affected. For years, this has lead to a more or less standard 
clinical target volume, including the primary tumor, the 
mesorectal fat and the presacral and internal iliac lymph 
node regions. However, given the limited number of 
recurrences after TME surgery, the standard clinical target 
volume can be seriously questioned. 
Another interesting application of endoluminal brachytherapy 
is the ability to increase the dose on the primary tumour. In 
elderly patients, standard surgery may be hampered by the 
